Rate My Professor Christopher Schultz

Christopher Schultz serves as Scientist-in-Charge of Bone Densitometry in the Department of Nuclear Medicine at Royal Adelaide Hospital, a position he has held since March 1987. His extensive research centers on bone mineral density evaluation using dual-energy X-ray absorptiometry (DXA), body composition measurements, osteoporosis diagnosis and management, sarcopenia, and metabolic alterations in diverse clinical populations. These include patients undergoing kidney and pancreas-kidney transplantation, those with inflammatory bowel disease, critical illness survivors, haemopoietic stem cell transplant recipients, and individuals with rheumatoid arthritis or chronic myeloid leukemia. Schultz's work emphasizes advanced hip analysis, trabecular bone score assessments, and correlations between bone health markers like carboxylated osteocalcin and fragility fractures in chronic kidney disease.

Schultz has authored or co-authored 56 publications, accumulating 1,418 citations as documented on ResearchGate. Notable contributions include 'Dual-Energy X-Ray Absorptiometry-Derived Advanced Hip Analysis and the Trabecular Bone Score Are Associated With the Diagnosis of Fracture Following Kidney and Simultaneous Pancreas-Kidney Transplantation' (2025), 'Higher carboxylated osteocalcin is an independent predictor of fragility fractures in chronic kidney disease' (2025), 'Automated micro-CT morphometry of femoral biopsies from haemodialysis patients' (2025), 'Incidence of Decreased Bone Mineral Density Post Allogeneic Haemopoietic Stem Cell Transplant: Single Institution Retrospective Analysis' (2023), 'Visceral Adipose Tissue Is Associated With Stricturing Crohn’s Disease Behavior, Fecal Calprotectin, and Quality of Life' (2018), 'Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia' (2018), 'Low muscle mass and sarcopenia: Common and predictive of osteopenia in inflammatory bowel disease' (2015), 'Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects' (2012), 'The Tyrosine Kinase Inhibitor Dasatinib Dysregulates Bone Remodeling Through Inhibition of Osteoclasts In Vivo' (2010), and 'Validation of the sheep as a large animal model for the study of vertebral osteoporosis' (2008). His collaborations frequently involve researchers from the University of Adelaide, contributing to advancements in clinical bone health research through precise densitometric techniques and longitudinal studies.